New Delhi: Bharat Biotech on Wednesday announced its Covid-19 vaccine candidate BBV152 Covaxin demonstrated 81% interim vaccine efficacy in its Phase 3 clinical trial. While the results are very encouraging and expected to boost confidence in the indigenously developed vaccine, however, it is important to understand that these are the first interim results based on 43 cases infected with the Covid-19 virus and the final results will determine the actual efficacy. Interim results from clinical trials help to analyze and predict the outcomes of a clinical trial. According to the Bharat Biotech, of the 43 cases around 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group, resulting in a point estimate of vaccine efficacy of 80.6%. The data is yet to be peer-reviewed. An additional interim analysis is awaited for 87 cases, and the final analysis is planned for 130 covid positive cases to analyse the actual efficacy data. To ... » Learn More about Explained: What Covaxin’s 81% interim vaccine efficacy means?